ZA200602716B - Plasminogen activators having reduced lysine binding company - Google Patents
Plasminogen activators having reduced lysine binding company Download PDFInfo
- Publication number
- ZA200602716B ZA200602716B ZA200602716A ZA200602716A ZA200602716B ZA 200602716 B ZA200602716 B ZA 200602716B ZA 200602716 A ZA200602716 A ZA 200602716A ZA 200602716 A ZA200602716 A ZA 200602716A ZA 200602716 B ZA200602716 B ZA 200602716B
- Authority
- ZA
- South Africa
- Prior art keywords
- plasminogen
- plasminogen activator
- activator
- dspa
- prp
- Prior art date
Links
- 102000001938 Plasminogen Activators Human genes 0.000 title claims description 29
- 108010001014 Plasminogen Activators Proteins 0.000 title claims description 29
- 229940127126 plasminogen activator Drugs 0.000 title claims description 29
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title description 8
- 239000004472 Lysine Substances 0.000 title description 7
- 230000002829 reductive effect Effects 0.000 title description 5
- ALPWRKFXEOAUDR-GKEJWYBXSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)([O-])=O)OC(=O)CCCCCCCCCCCCCCCCC ALPWRKFXEOAUDR-GKEJWYBXSA-M 0.000 claims description 35
- 102000013566 Plasminogen Human genes 0.000 claims description 26
- 108010051456 Plasminogen Proteins 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 22
- 239000012190 activator Substances 0.000 claims description 9
- 230000007704 transition Effects 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 80
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 80
- 229960000187 tissue plasminogen activator Drugs 0.000 description 76
- 102000009123 Fibrin Human genes 0.000 description 27
- 108010073385 Fibrin Proteins 0.000 description 27
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 27
- 229950003499 fibrin Drugs 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108010049003 Fibrinogen Proteins 0.000 description 11
- 102000008946 Fibrinogen Human genes 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 229940012952 fibrinogen Drugs 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 238000001994 activation Methods 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 230000003197 catalytic effect Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 230000033885 plasminogen activation Effects 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 230000002537 thrombolytic effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 6
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 5
- 102000029797 Prion Human genes 0.000 description 5
- 108091000054 Prion Proteins 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000003811 finger Anatomy 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
- 241000288900 Desmodus rotundus Species 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 108010088842 Fibrinolysin Proteins 0.000 description 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 3
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 229920001420 poly(caprolactone-co-lactic acid) Polymers 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 101100510326 Caenorhabditis elegans tpa-1 gene Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010039185 Tenecteplase Proteins 0.000 description 2
- 229940099983 activase Drugs 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 108010051412 reteplase Proteins 0.000 description 2
- 229960002917 reteplase Drugs 0.000 description 2
- 229960000216 tenecteplase Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 108010057987 Desmodus rotundus salivary plasminogen activator alpha 1 Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000657326 Homo sapiens Protein TANC2 Proteins 0.000 description 1
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 1
- 206010022528 Interactions Diseases 0.000 description 1
- 108010031891 KHRR 296-299 AAAA T103N Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 241001237728 Precis Species 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 102100034784 Protein TANC2 Human genes 0.000 description 1
- 241000282941 Rangifer tarandus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000022563 Rema Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 229950001282 desmoteplase Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 102000047823 human PLAT Human genes 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 108010051044 lanoteplase Proteins 0.000 description 1
- 229950010645 lanoteplase Drugs 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010087750 lysyl-plasminogen Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- QLNWXBAGRTUKKI-UHFFFAOYSA-N metacetamol Chemical compound CC(=O)NC1=CC=CC(O)=C1 QLNWXBAGRTUKKI-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10342518A DE10342518A1 (de) | 2003-09-12 | 2003-09-12 | Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200602716B true ZA200602716B (en) | 2007-07-25 |
Family
ID=34305758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200602716A ZA200602716B (en) | 2003-09-12 | 2004-09-13 | Plasminogen activators having reduced lysine binding company |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP1664293A2 (fr) |
| JP (1) | JP2007505079A (fr) |
| CN (1) | CN1849394A (fr) |
| AU (1) | AU2004272731A1 (fr) |
| BR (1) | BRPI0413718A (fr) |
| CA (1) | CA2537696A1 (fr) |
| DE (1) | DE10342518A1 (fr) |
| EA (2) | EA011156B1 (fr) |
| IL (1) | IL173953A0 (fr) |
| MX (1) | MXPA06002756A (fr) |
| NO (1) | NO20061646L (fr) |
| NZ (1) | NZ545825A (fr) |
| WO (1) | WO2005026341A2 (fr) |
| ZA (1) | ZA200602716B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8430749B2 (en) | 2001-08-10 | 2013-04-30 | Igt | Dynamic casino tracking and optimization |
| US7946917B2 (en) | 2001-08-10 | 2011-05-24 | Igt | Flexible loyalty points programs |
| DE10153601A1 (de) | 2001-11-02 | 2003-05-22 | Paion Gmbh | DSPA zur Behandlung von Schlaganfall |
| DE10342518A1 (de) | 2003-09-12 | 2005-05-12 | Paion Gmbh | Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität |
| IL190184A0 (en) * | 2008-03-16 | 2009-02-11 | Hadasit Med Res Service | tPA MUTANT IN THE TREATMENT OF ACUTE BRAIN INJURY AND NEURODEGENERATIVE DISORDERS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US5094953A (en) * | 1988-03-21 | 1992-03-10 | Genentech, Inc. | Human tissue plasminogen activator variants |
| DK176140B1 (da) * | 1988-07-20 | 2006-09-25 | Schering Ag Patentabteilung | Flagermusspyt-plasminogenaktivatorer |
| DE3825253A1 (de) * | 1988-07-25 | 1990-02-01 | Boehringer Mannheim Gmbh | T-pa-derivat und seine herstellung |
| US5714145A (en) * | 1988-09-02 | 1998-02-03 | Genentech, Inc. | Tissue plasminogen activator having zymogenic or fibrin specific properties |
| US6008019A (en) | 1989-02-13 | 1999-12-28 | Schering Aktiengesellschaft | Plasminogen activator from saliva of the vampire bat |
| EP0383417B1 (fr) | 1989-02-13 | 1995-12-27 | Schering Aktiengesellschaft | Activateur du plasminogène salivaires de chauve-souris vPA-alpha 1 |
| DE69215537T2 (de) * | 1991-12-16 | 1997-04-30 | Genentech, Inc., South San Francisco, Calif. | t-PA SUBSTITUTIONSVARIANTEN MIT VERBESSERTER FIBRINSPEZIFITÄT |
| DE4423574A1 (de) * | 1994-07-05 | 1996-01-11 | Boehringer Mannheim Gmbh | Nicht-glykosylierte Plasminogenaktivator-Derivate und ihre Verwendung bei erhöhtem Blutungsrisiko |
| DE10153601A1 (de) * | 2001-11-02 | 2003-05-22 | Paion Gmbh | DSPA zur Behandlung von Schlaganfall |
| BRPI0409865A (pt) * | 2003-05-02 | 2006-05-16 | Paion Deutschland Gmbh | injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia |
| DE10342518A1 (de) | 2003-09-12 | 2005-05-12 | Paion Gmbh | Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität |
-
2003
- 2003-09-12 DE DE10342518A patent/DE10342518A1/de not_active Withdrawn
-
2004
- 2004-09-13 BR BRPI0413718-3A patent/BRPI0413718A/pt not_active IP Right Cessation
- 2004-09-13 NZ NZ545825A patent/NZ545825A/en unknown
- 2004-09-13 CN CNA2004800260817A patent/CN1849394A/zh active Pending
- 2004-09-13 EA EA200600573A patent/EA011156B1/ru not_active IP Right Cessation
- 2004-09-13 EP EP04765139A patent/EP1664293A2/fr not_active Withdrawn
- 2004-09-13 EP EP10011604A patent/EP2368984A1/fr not_active Withdrawn
- 2004-09-13 AU AU2004272731A patent/AU2004272731A1/en not_active Abandoned
- 2004-09-13 ZA ZA200602716A patent/ZA200602716B/en unknown
- 2004-09-13 WO PCT/EP2004/010220 patent/WO2005026341A2/fr not_active Ceased
- 2004-09-13 CA CA002537696A patent/CA2537696A1/fr not_active Abandoned
- 2004-09-13 EA EA200801861A patent/EA200801861A1/ru unknown
- 2004-09-13 JP JP2006525786A patent/JP2007505079A/ja active Pending
- 2004-09-13 MX MXPA06002756A patent/MXPA06002756A/es unknown
-
2006
- 2006-02-27 IL IL173953A patent/IL173953A0/en unknown
- 2006-04-11 NO NO20061646A patent/NO20061646L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA200600573A1 (ru) | 2006-08-25 |
| WO2005026341A3 (fr) | 2005-09-01 |
| EA011156B1 (ru) | 2009-02-27 |
| EP2368984A1 (fr) | 2011-09-28 |
| EP1664293A2 (fr) | 2006-06-07 |
| IL173953A0 (en) | 2006-07-05 |
| DE10342518A1 (de) | 2005-05-12 |
| NZ545825A (en) | 2009-08-28 |
| BRPI0413718A (pt) | 2006-10-17 |
| NO20061646L (no) | 2006-04-11 |
| MXPA06002756A (es) | 2007-08-24 |
| CA2537696A1 (fr) | 2005-03-24 |
| CN1849394A (zh) | 2006-10-18 |
| JP2007505079A (ja) | 2007-03-08 |
| AU2004272731A1 (en) | 2005-03-24 |
| WO2005026341A2 (fr) | 2005-03-24 |
| EA200801861A1 (ru) | 2010-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stennicke et al. | Catalytic properties of the caspases | |
| Gething et al. | Variants of human tissue‐type plasminogen activator that lack specific structural domains of the heavy chain. | |
| Ryu et al. | Porcine kallikrein‐4 activation, glycosylation, activity, and expression in prokaryotic and eukaryotic hosts | |
| US5225537A (en) | Methods for producing hybrid phospholipid-binding proteins | |
| US5453373A (en) | Protein C derivatives | |
| Page et al. | Determinants of specificity in coagulation proteases | |
| US20100028910A1 (en) | Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity | |
| JP3270462B2 (ja) | ハイブリッドプロテインｃ | |
| Paoni et al. | Making tissue-type plasminogen activator more fibrin specific | |
| EP0383417A1 (fr) | Activateur du plasminogène salivaires de chauve-souris vPA-alpha 1 | |
| EP0323149A2 (fr) | Vecteurs et composés pour l'expression de formes zymogéniques de protéine C | |
| Stürzebecher et al. | Mapping of the catalytic site of CHO‐t‐PA and the t‐PA variant BM 06.022 by synthetic inhibitors and substrates | |
| CA2271697C (fr) | Variantes d'activateur plasminogene de type tissulaire (t-pa): compositions et techniques d'utilisation | |
| US6133011A (en) | Chimeric proteins having fibrinolytic and thrombin-inhibiting properties | |
| Yu et al. | Construction, expression, and properties of a recombinant chimeric human protein C with replacement of its growth factor-like domains by those of human coagulation factor IX | |
| CA2537696A1 (fr) | Activateurs plasminogenes a capacite de liaison lysine reduite | |
| Kluft | Tissue-type plasminogen activator (t-PA): physiological and clinical aspects | |
| Rezaie et al. | Proline at the P2 position in protein C is important for calcium-mediated regulation of protein C activation and secretion | |
| Barnewitz et al. | Unaltered prion protein cleavage in plasminogen-deficient mice | |
| Holly et al. | Resistance to Inhibition by. alpha.-1-Anti-Trypsin and Species Specificity of a Chimeric Human/Bovine Protein C | |
| WO2000049871A1 (fr) | Proteine kringle antiangiogenique et ses mutants | |
| Lijnen et al. | Molecular mechanism of fibrinolysis | |
| US20040214280A1 (en) | Novel polypeptides and coagulation therapy | |
| Stump et al. | Biochemical and biological properties of single-chain urokinase-type plasminogen activator | |
| Ong et al. | The plasminogen activator and esterase activities of the two forms of urokinase |